STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Ionis to present at upcoming investor conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025
  • TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025
  • Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025
  • Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025
  • UBS Virtual CNS Day 2025 on Monday, March 17, 2025
  • Stifel 2025 Virtual CNS Forum on Wednesday, March 19, 2025

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.

Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – ir@ionis.com 760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – media@ionis.com – 760-603-4679

Source: Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

13.40B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD